dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2016-01-28T16:56:31Z
dc.date.available2016-01-28T16:56:31Z
dc.date.created2016-01-28T16:56:31Z
dc.date.issued2011
dc.identifierPharmaceuticals, v. 4, p. 1450-1474, 2011.
dc.identifier1424-8247
dc.identifierhttp://hdl.handle.net/11449/133761
dc.identifier10.3390/ph4111450
dc.identifierISSN1424-8247-2011-04-1450-1474.pdf
dc.identifier4083068210623663
dc.identifier3204277043366119
dc.identifier5435899068903487
dc.identifier9734333607975413
dc.identifier5737933639516944
dc.identifier0000-0003-4141-0455
dc.description.abstractThe design of new drugs with better physiochemical properties, adequateabsorption, distribution, metabolism, and excretion, effective pharmacologic potency andlacking toxicity remains is a challenge. Inflammation is the initial trigger of severaldifferent diseases, such as Alzheimer s disease, asthma, atherosclerosis, colitis, rheumatoidarthritis, depression, cancer; and disorders such as obesity and sexual dysfunction.Although inflammation is not the direct cause of these disorders, inflammatory processesoften increase related pain and suffering. New anti-inflammatory drugs developed usingmolecular hybridization techniques to obtain multiple-ligand drugs can act at one or multipletargets, allowing for synergic action and minimizing toxicity. This work is a review of newanti-inflammatory drugs developed using the molecular modification approach.
dc.languageeng
dc.relationPharmaceuticals
dc.relation1,293
dc.rightsAcesso aberto
dc.sourceCurrículo Lattes
dc.subjectAnti-inflammatory
dc.subjectHybridization
dc.subjectMultiple-ligands
dc.subjectMutual prodrug
dc.titleAnti-inflammatory drug design by molecular hybridization approach
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución